Skip to main content
. 2021 Mar 6;26(7):610–618. doi: 10.1002/onco.13730

Figure 1.

Figure 1

Consort diagram shows the selection of patients who were included in the analyses reported here. The four original arms included the following: (1) clobetasol + regorafenib (starting dose 80 mg per day with a potential dose escalation to 160 mg per day); (2) reactive clobetasol + regorafenib (starting dose 80 mg per day with a potential dose escalation to 160 mg per day); (3) preemptive clobetasol + regorafenib (160 mg starting dose); and (4) reactive clobetasol + regorafenib (160 mg starting dose).